Moneycontrol PRO
HomeNewsBusinessCompaniesBiovet to expand animal vaccine capacity, will invest Rs 200 crore

Biovet to expand animal vaccine capacity, will invest Rs 200 crore

The process once completed would make Biovet one of the world's largest FMD vaccine makers. It would compete against the Indian Immunologicals (IIL), a National Dairy Development Board subsidiary.

June 20, 2019 / 17:42 IST

Biovet on June 20 said it will invest Rs 200 crore to expand existing facilities at Malur in Karnataka to make vaccines for Foot & Mouth Disease (FMD) and Brucellosis disease.

The animal vaccine company will manufacture 200 million doses of the FMD vaccine and 100 million doses of the Brucella vaccine, pushing the company's overall capacity from 200 million to 500 million doses.

The process once completed would make Biovet one of the world's largest FMD vaccine makers. It would compete against the Indian Immunologicals (IIL), a National Dairy Development Board subsidiary.

With a capacity to produce 360 million doses, IIL is the world’s top FMD vaccine producer and supplies around 80 percent of the doses for the control programme in India.

"Our plant is the first BSL-3PlusAg production facility established in Asia and second the world. Our independent production lines for three separate serotype FMD viruses, on completion will be the first of its kind in the world. Further, the new facility for Brucella Vaccines will place Biovet, as the world’s largest manufacturer of this vaccine," Dr Panduranga Rao, VP of Biovet said.

According to estimates, India’s FMD control programme requires 1,000 million doses each year, whereas the country's current production capacity is around 500 million doses. There is an unmet need for 500 million doses, and Biovet aims to bridge this gap.

Established in 2006, Biovet, promoted by Krishna Ella, the Founder-Chairman of Bharat Biotech, has a license to produce Hemorrhagic Septicaemia vaccine for cattle and buffaloes. Enterotoxaemia vaccine for sheep and goats, and Black quarter vaccine for cattle and buffaloes.

The company is also first in India and second in the world to develop and market Johne’s disease vaccine.

Viswanath Pilla
Viswanath Pilla is a business journalist with 14 years of reporting experience. Based in Mumbai, Pilla covers pharma, healthcare and infrastructure sectors for Moneycontrol.
first published: Jun 20, 2019 05:42 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Subscribe to Tech Newsletters

  • On Saturdays

    Find the best of Al News in one place, specially curated for you every weekend.

  • Daily-Weekdays

    Stay on top of the latest tech trends and biggest startup news.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347